SCHEMBL6691098

SCHEMBL6691098

COC(=O)C1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@H]3CC[C@@]21C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.79
▸ SHBG P04278 6/20 0.79
▸ SMN1; SMN2 Q16637 5/20 0.79
▸ SERPINA6 P08185 5/20 0.79
▸ BLM P54132 4/20 0.79
▸ CYP2C19 P33261 3/20 0.79
▸ NR3C1 P04150 3/20 0.79
▸ MEN1 O00255 2/20 0.79
▸ KMT2A Q03164 2/20 0.79
▸ MAPT P10636 2/20 0.79
▸ ADORA3 P0DMS8 1/20 0.79
▸ MAPK3 P27361 1/20 0.79
▸ SLC6A3 Q01959 1/20 0.79
▸ HSD17B10 Q99714 5/20 0.74
▸ TSHR P16473 3/20 0.74
▸ HIF1A Q16665 3/20 0.74
▸ PMP22 Q01453 3/20 0.74
▸ CYP3A4 P08684 1/20 0.74
▸ ALDH1A1 P00352 3/20 0.71
▸ PGR P06401 2/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6691094 1.00 LMNA (0.79) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL14523053 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL3931615 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL14546356 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL24287585 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL23456341 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL18261234 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL13558389 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
Hydroxyprogesterone SCHEMBL265609 0.88 LMNA (1.00) LMNASHBGSMN1; SMN2SERPINA6BLM
SCHEMBL4443903 0.88 LMNA (0.83) LMNASHBGSMN1; SMN2SERPINA6BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040082556-A1 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use ENDORECHERCHE, INC. 2004-04-29 — — US disclosed
EP-1321146-A2 Inhibitors of type 5 and 3 17beta-hydroxysteroid dehydrogenase and methods for their use Endorecherche Inc. (CA) 2003-06-25 — — EP disclosed
US-6541463-B1 17-spirolactone derivatives of steroids ENDORECHERCHE, INC. (CA) 2003-04-01 — — US disclosed
EP-1094798-A2 INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE Endorecherche Inc. (CA) 2001-05-02 — — EP disclosed
WO-1999046279-A2 INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE ENDORECHERCHE, INC. (CA) 1999-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082556-A1 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use HSD17B11, HSD17B3, HSD17B1 LMNA 3211/4885SHBG 33/4885SMN1; SMN2 3214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback